As of November 6, 2026, Ovid Therapeutics Inc. is a publicly traded company (Nasdaq: OVID); its largest reported holder is RA Capital, with 9.9% on Schedule 13G/A of August 14, 2026, then Sirenia Capital Management LP (9.9%). The largest insider holding is Takeda Pharmaceutical Co. Ltd., a 10% owner, with 8,781,996 shares (4.5% of shares outstanding), per Form 4 of December 9, 2025 (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Ovid Therapeutics Inc.? See the free Snapshot first.
Free to see. No signup.
Is Ovid Therapeutics Inc. a real, registered company?
- Ovid Therapeutics Inc. files with the SEC under CIK 1636651 (its SEC filings).
- Its shares are listed under the ticker OVID on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in New York, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Ovid Therapeutics Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Charles Carter, Chief Financial Officer (Form 8-K filed 2026-07-08). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names ADAR1 Capital (filed 2026-08-14).
Who are Ovid Therapeutics Inc.'s owners and officers?
Ovid Therapeutics Inc.: incorporated in Delaware; business address in New York, New York; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-08-14).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-08-14 | Adar1 Capital Management, LLC | 5.1% |
| Schedule 13G/A, 2026-08-14 | Balyasny Asset Management L.P. | 4.99% |
| Schedule 13G/A, 2026-08-14 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2026-08-14 | Eventide Asset Management, LLC | 6.3% |
| Schedule 13G/A, 2026-08-13 | Affinity Asset Advisors, LLC | 7.9% |
| Schedule 13G, 2026-07-29 | Blackrock, Inc. | 5.8% |
| Schedule 13G/A, 2026-07-08 | Federated Hermes, Inc. | 4.15% |
| Schedule 13G, 2026-05-15 | Balyasny Asset Management L.P. | 5.33% |
| Schedule 13G, 2026-05-15 | Eventide Asset Management, LLC | 7.3% |
| Schedule 13G, 2026-05-15 | Sirenia Capital Management LP | 9.9% |
| Schedule 13G/A, 2026-05-15 | Point72 Asset Management, L.P. | 1.3% |
| Schedule 13G/A, 2026-05-14 | Affinity Asset Advisors, LLC | 9.1% |
Questions about who owns Ovid Therapeutics Inc.
Who owns Ovid Therapeutics Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of Ovid Therapeutics Inc.: Ra Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), Sirenia Capital Management LP (9.9%, Schedule 13G, filed 2026-05-15), Affinity Asset Advisors, LLC (7.9%, Schedule 13G/A, filed 2026-08-13), Eventide Asset Management, LLC (6.3%, Schedule 13G/A, filed 2026-08-14) and Blackrock, Inc. (5.8%, Schedule 13G, filed 2026-07-29); 1 more is listed above.
Who are the largest shareholders of Ovid Therapeutics Inc.?
By the share each holder's latest filing reports, the largest holders of Ovid Therapeutics Inc. on this page are Ra Capital Management, L.P. (9.9%), Sirenia Capital Management LP (9.9%) and Affinity Asset Advisors, LLC (7.9%).
When did Ra Capital Management, L.P. buy into Ovid Therapeutics Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13G/A, filed 2026-08-14, reporting 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Ovid Therapeutics Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ovid Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ovid Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-08 | Charles Carter | Chief Financial Officer | appointed |
Which insiders own Ovid Therapeutics Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Takeda Pharmaceutical Co. Ltd., a 10% owner: 8,781,996 shares (4.5% of shares outstanding), 1,781,996 held directly and 7,000,000 indirectly, on a joint filing (Form 4, 2025-12-09).
- Takeda Pharmaceuticals U.S.A., Inc., a 10% owner: 8,781,996 shares (4.5% of shares outstanding), 1,781,996 held directly and 7,000,000 indirectly, on a joint filing (Form 4, 2025-12-09).
- , the chairman and a director: 3,770,509 shares (1.9% of shares outstanding), 3,735,048 held directly and 35,461 indirectly (Form 4, 2026-03-25).
- , a director: 217,578 shares (0.11% of shares outstanding) (Form 4, 2026-04-09).
- , the cbfo: 156,313 shares (0.08% of shares outstanding) (Form 4, 2026-03-02).
Shares outstanding: 195,297,857 as of 2026-08-11, from the company's latest SEC cover page.
How much has Ovid Therapeutics Inc. raised?
No fundraising or offering filing from Ovid Therapeutics Inc. is on file with us.
Keep reading
More on Ovid Therapeutics Inc. and the records around it.
Ovid Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Jul 2026
Companies that share a holder
- Eventide Asset Management, LLC also filed stake reports on 9 other companies: Immix Biopharma, Inc. (Aug 2026), Beta Bionics, Inc. (May 2026), COLLEGIUM PHARMACEUTICAL, INC (May 2026)
- Affinity Asset Advisors, LLC also filed stake reports on 13 other companies: Amanat Acquisition Corp. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Equillium Inc. (Aug 2026)
- Federated Hermes, Inc. also filed stake reports on 13 other companies: EyePoint (Nov 2026), Arcturus Therapeutics Holdings Inc. (Oct 2026), Forte Biosciences, Inc. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/ovid-therapeutics